This article is more than 5 years old. Information may no longer be current.

InSite Vision to advance ocular anti-inflammatory candidate into clinical trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — InSite Vision has announced plans to advance a new ocular anti-inflammatory candidate for reducing pain and swelling after ocular surgery into clinical trials, according to a press release from the company.

The compound, called ISV-303, is a formulation of a low concentration of bromfenac and the company's DuraSite drug delivery vehicle. In preclinical studies, ISV-303 showed superior efficacy as a delivery vehicle with good ocular distribution to both the anterior and posterior segments when compared with a commercially available product. InSite expects to present data from its preclinical studies at an upcoming scientific meeting, according to the release.

The company plans to advance ISV-303 into clinical studies after completing Investigational New Drug-enabling toxicology studies in the first half of 2010.